These findings could explain, to a certain degree, why lactadherin protein is enriched in sEV-MDA231 compared to the other sEVs analyzed (Fig. 4D) and become relevant because it suggests that lactadherin can be blocked with antibodies or specific peptides; thus, it could be used as a target in adjuvant combined BC therapy. This evidence concerns the gene MFGE8 and breast cancer.